Mycobacterium abscessus y kansasii tratados satisfactoriamente con amikacina inhalada: Reporte de caso

Percy C. Ramirez; Alex Campos-Huaman; Jossmert  Segama-Gonzales; Raúl  Montalvo-Otivo

doi:10.35434/rcmhnaaa.2024.174.2357

Authors

Percy C. Ramirez Universidad Nacional del Centro del Perú, Facultad de Medicina Humana, Huancayo, Perú.
Alex Campos-Huaman Universidad Nacional del Centro del Perú, Facultad de Medicina Humana, Huancayo, Perú.
Jossmert Segama-Gonzales Universidad Nacional del Centro del Perú, Facultad de Medicina Humana, Huancayo, Perú.
Raúl Montalvo-Otivo Universidad Nacional del Centro del Perú, Facultad de Medicina Humana, Huancayo, Perú.

DOI:

https://doi.org/10.35434/rcmhnaaa.2024.174.2357

Keywords:

Mycobacterium, Nontuberculous Mycobacteria, Mycobacterium abscessus, Mycobacterium kansasii, Amikacin

Abstract

Introduction: Pulmonary infections by nontuberculous mycobacteria (NTM) represent a serious clinical problem because they produce progressive, severe and difficult to treat pictures. Case report: We present two patients without immunosuppressive comorbidity with pulmonary infection by Mycobacterium abscessus and Mycobacterium kansasii, with clinical and radiographic improvement after receiving inhalation amikacin. The use of this drug added to standard therapy allowed a favorable evolution due to its high concentration in the alveolar tissue in infection by non-tuberculous mycobacteria. Discussion: Initial therapy to treat NTM infections based on a macrolide, ethambutol and rifampicin is often not sufficient. Inhalation amikacin is proposed as rescue therapy due to its potent antimicrobial activity, achieving a high concentration and a longer time in lung tissue with less toxic effects. Conclusion: A favorable clinical response was evidenced with the combined treatment with inhaled amikacin.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Percy C. Ramirez, Universidad Nacional del Centro del Perú, Facultad de Medicina Humana, Huancayo, Perú.

1. Estudiante de Medicina.

Alex Campos-Huaman, Universidad Nacional del Centro del Perú, Facultad de Medicina Humana, Huancayo, Perú.

1. Estudiante de Medicina.

Jossmert Segama-Gonzales, Universidad Nacional del Centro del Perú, Facultad de Medicina Humana, Huancayo, Perú.

1. Estudiante de Medicina.

Raúl Montalvo-Otivo , Universidad Nacional del Centro del Perú, Facultad de Medicina Humana, Huancayo, Perú.

1. Médico infectólogo.

References

Boudehen YM, Kremer L. Mycobacterium abscessus. Trends Microbiol. 2021;29(10):951-952. doi: 10.1016/j.tim.2021.06.006.

Thomson RM, Tolson C, Sidjabat HE, et al. Increasing prevalence of nontuberculous mycobacteria in Queensland, Australia, 1999–2008. Thorax. doi: 2013;68(10):1007-1008.

Khan O, Chaudary N. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults. Drug Des Devel Ther. 2020;14:2287-2294. doi: 10.2147/DDDT.S146111.

Tachibana K, Okada Y, Matsuda Y, Miyoshi K, Oto T, Chen-Yoshikawa TF, et al. Nontuberculous mycobacterial and Aspergillus infections among cadaveric lung transplant recipients in Japan. Respir Investig. 2018;56(3):243-248. doi: 10.1016/j.resinv.2017.12.010.

Informe mundial sobre la tuberculosis. Ginebra: Organización Mundial de la Salud; 2023 [Internet]. Ginebra, Suiza: OMS; 2023 [Citado el 22 de enero del 2024]. Disponible en: https://acortar.link/XilNxY

Buendía JA, Guerrero Patiño D, Zuluaga Salazar AF. Efficacy of adjunctive inhaled colistin and tobramycin for ventilator-associated pneumonia: systematic review and meta-analysis. BMC Pulm Med. 2024;24(1):213. doi: 10.1186/s12890-024-03032-7.

Vardakas KZ, Voulgaris GL, Samonis G, Falagas ME. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51(1):1-9. doi: 10.1016/j.ijantimicag.2017.05.016.

Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013;19(11):1889-91. doi: 10.3201/eid1911.130737.

Van Ingen J, Kuijper EJ. Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol. 2014;9(9):1095-110. doi: 10.2217/fmb.14.60.

Zhang J, Leifer F, Rose S, Chun DY, Thaisz J, Herr T, et al. Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages. Front Microbiol. 2018;9:915. doi: 10.3389/fmicb.2018.00915.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.

Esteban J, Navas E. Treatment of infections caused by nontuberculous mycobacteria. Enferm Infecc Microbiol Clin (Engl Ed). 2018;36(9):586-592. doi: 10.1016/j.eimc.2017.10.008.

Wagner D, Lange C. Lungenerkrankung durch nicht-tuberkulöse Mykobakterien – Die neue ATS/ERS/ESCMID/IDSA-Leitlinie [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline]. Dtsch Med Wochenschr. 2020;145(16):1145-1151. German. doi: 10.1055/s-0043-124159.

Moore RR, Holder D, Earnest S. Diagnosing and treating Mycobacterium kansasii. JAAPA. 2022;35(7):32-34. doi: 10.1097/01.JAA.0000824932.43060.3f.

ohansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020;18(7):392-407. doi: 10.1038/s41579-020-0331-1.

Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. ; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416. doi: 10.1164/rccm.200604-571ST.

Patrón-Ordóñez G, Llanos-Tejada F, Benites-Gamboa D, Espinoza-Chiong C. Coinfección por Mycobacterium abscessus y Mycobacterium tuberculosis en un paciente con síndrome de Cushing exógeno y otras comorbilidades. Rev Peru Med Exp Salud Publica. 2020;37(4):762-766. doi: 10.17843/rpmesp.2020.374.5296.

Huang HL, Lu PL, Lee CH, Chong IW. Treatment of pulmonary disease caused by Mycobacterium kansasii. J Formos Med Assoc. 2020;119 Suppl 1:S51-S57. doi: 10.1016/j.jfma.2020.05.018.